Cited by 174Barrier Structure and Function StudiesDrug Transport and Resistance MechanismsNanoparticle-Based Drug Delivery

Carrier-mediated or specialized transport of drugs across the blood–brain barrier

Tsuji, Akira, Tamai, Ikumi·1999·Advanced Drug Delivery Reviews

Abstract

In the drug development process, it remains a difficult task to regulate the entry of the drugs. However, recent progress in studies of the transporter-mediated influx and efflux of endogenous and exogenous compounds, including synthetic drugs, across the blood-brain barrier (BBB) is beginning to provide a rational basis for controlling drug distribution to the brain. This paper describes mechanisms established in the last decade for carrier-mediated influx and efflux of drugs and endocytosis of biologically active peptides across the BBB. The transport systems at the BBB described here are the uptake transporters for nutrients, such as amino acids and hexoses, monocarboxylates, amines, carnitine and glutathione and efflux transporters, such as P-glycoprotein and multiple organic anion transporters. Delivery of cationized peptides across the BBB via adsorptive-mediated endocytosis is also described. By utilizing such highly specific transport mechanisms, it should be possible to establish strategies to regulate the entry of candidate drugs, including peptides, into the brain.

Integrity signals

Registry

Crossref · 10.1016/s0169-409x(98)00084-2

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Passive transcytosis across the blood-brain barrier permits only hydrophilic compounds with a mass lower than 150 Da and highly hydrophobic compounds with a mass lower than 400-600 Da.

    “The tightness of the BBB precludes the entrance of most pharmaceuticals into the brain via passive transcytosis, except for hydrophilic compounds which have a mass lower than 150 Da and highly hydrophobic compounds which have a mass lower than 400–600 Da.157,158”

Cited by

Sorted by citations

Authors
Tsuji, A., & Tamai, I.
Affiliations
Kanazawa University (JP)
Corresponding author
Tsuji, Akira
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
1999-04
Volume
36
Issue
2-3
Pages
277-290
ISSN
0169-409X (ISSN-L)
OpenAlex
W1992983740
Cited by
174
References
0
Citations by year
2026: 2 · 2025: 8 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 5 · 2012: 2
FWCI
0.67
Type
journal article
Language
en
Open access
closed
Locations
  • Advanced Drug Delivery Reviews (publishedVersion)
  • PubMed (publishedVersion)
Funders
Ministry of Education, Culture, Sports, Science and Technology
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
blood-brain barrier, drug transport, carrier-mediated transport, efflux pumps, P-glycoprotein, organic anion transporters, amino acid transporters, hexose transporters, monocarboxylate transporters, carnitine transport, glutathione transport, endocytosis, brain drug delivery, brain drug distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review